Annual EBITDA
-$41.71 M
+$3.23 M+7.19%
31 December 2023
Summary:
Oncternal Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$41.71 million, with the most recent change of +$3.23 million (+7.19%) on 31 December 2023. During the last 3 years, it has fallen by -$24.17 million (-137.80%). ONCT annual EBITDA is now -350.23% below its all-time high of $16.67 million, reached on 31 December 2010.ONCT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$8.68 M
+$182.00 K+2.05%
30 September 2024
Summary:
Oncternal Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$8.68 million, with the most recent change of +$182.00 thousand (+2.05%) on 30 September 2024. Over the past year, it has increased by +$1.71 million (+16.45%). ONCT quarterly EBITDA is now -119.42% below its all-time high of $44.70 million, reached on 31 March 2010.ONCT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$35.96 M
+$1.71 M+4.54%
30 September 2024
Summary:
Oncternal Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$35.96 million, with the most recent change of +$1.71 million (+4.54%) on 30 September 2024. Over the past year, it has increased by +$8.03 million (+18.26%). ONCT TTM EBITDA is now -315.71% below its all-time high of $16.67 million, reached on 31 December 2010.ONCT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ONCT EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7.2% | +16.4% | +18.3% |
| 3 y3 years | -137.8% | +9.9% | -37.5% |
| 5 y5 years | -6.9% | -75.4% | -79.9% |
ONCT EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -137.8% | +7.2% | -7.4% | +28.5% | -37.5% | +23.8% |
| 5 y | 5 years | -177.7% | +7.2% | -203.4% | +28.5% | -106.5% | +23.8% |
| alltime | all time | -350.2% | +21.2% | -119.4% | +37.7% | -315.7% | +28.8% |
Oncternal Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$8.68 M(-2.1%) | -$35.96 M(-4.5%) |
| June 2024 | - | -$8.86 M(+1.0%) | -$37.67 M(-1.8%) |
| Mar 2024 | - | -$8.78 M(-8.9%) | -$38.35 M(-8.1%) |
| Dec 2023 | -$41.71 M(-7.2%) | -$9.64 M(-7.3%) | -$41.71 M(-5.2%) |
| Sept 2023 | - | -$10.39 M(+8.9%) | -$43.99 M(-2.1%) |
| June 2023 | - | -$9.54 M(-21.4%) | -$44.93 M(-4.8%) |
| Mar 2023 | - | -$12.14 M(+1.9%) | -$47.18 M(+5.0%) |
| Dec 2022 | -$44.95 M(+43.3%) | -$11.91 M(+5.2%) | -$44.95 M(+9.3%) |
| Sept 2022 | - | -$11.32 M(-4.0%) | -$41.11 M(+4.3%) |
| June 2022 | - | -$11.79 M(+19.0%) | -$39.42 M(+11.6%) |
| Mar 2022 | - | -$9.91 M(+22.7%) | -$35.32 M(+12.6%) |
| Dec 2021 | -$31.37 M(+78.8%) | -$8.08 M(-16.2%) | -$31.37 M(+20.0%) |
| Sept 2021 | - | -$9.64 M(+25.3%) | -$26.15 M(+25.1%) |
| June 2021 | - | -$7.69 M(+29.0%) | -$20.91 M(+11.5%) |
| Mar 2021 | - | -$5.96 M(+108.3%) | -$18.75 M(+6.9%) |
| Dec 2020 | -$17.54 M(+16.8%) | -$2.86 M(-34.9%) | -$17.54 M(-7.0%) |
| Sept 2020 | - | -$4.39 M(-20.6%) | -$18.86 M(-2.9%) |
| June 2020 | - | -$5.54 M(+16.5%) | -$19.42 M(+11.5%) |
| Mar 2020 | - | -$4.75 M(+13.6%) | -$17.41 M(-6.3%) |
| Dec 2019 | -$15.02 M(-61.5%) | -$4.18 M(-15.5%) | -$18.59 M(-7.0%) |
| Sept 2019 | - | -$4.95 M(+40.1%) | -$19.98 M(-18.9%) |
| June 2019 | - | -$3.53 M(-40.4%) | -$24.65 M(-21.2%) |
| Mar 2019 | - | -$5.93 M(+6.4%) | -$31.27 M(-19.9%) |
| Dec 2018 | -$39.01 M(+27.5%) | -$5.57 M(-42.0%) | -$39.01 M(-8.9%) |
| Sept 2018 | - | -$9.62 M(-5.2%) | -$42.83 M(+2.6%) |
| June 2018 | - | -$10.15 M(-25.8%) | -$41.73 M(+9.8%) |
| Mar 2018 | - | -$13.68 M(+45.7%) | -$38.02 M(+24.2%) |
| Dec 2017 | -$30.61 M(+18.2%) | -$9.39 M(+10.2%) | -$30.61 M(+9.0%) |
| Sept 2017 | - | -$8.52 M(+32.4%) | -$28.07 M(+6.0%) |
| June 2017 | - | -$6.43 M(+2.6%) | -$26.47 M(+1.5%) |
| Mar 2017 | - | -$6.27 M(-8.5%) | -$26.09 M(+0.7%) |
| Dec 2016 | -$25.91 M(+18.8%) | -$6.85 M(-1.0%) | -$25.91 M(+3.6%) |
| Sept 2016 | - | -$6.92 M(+14.3%) | -$25.00 M(+4.4%) |
| June 2016 | - | -$6.05 M(-0.5%) | -$23.94 M(+4.8%) |
| Mar 2016 | - | -$6.08 M(+2.2%) | -$22.84 M(+4.8%) |
| Dec 2015 | -$21.80 M(-27.9%) | -$5.95 M(+1.6%) | -$21.80 M(+2.4%) |
| Sept 2015 | - | -$5.86 M(+18.3%) | -$21.29 M(+4.5%) |
| June 2015 | - | -$4.95 M(-1.8%) | -$20.37 M(-22.7%) |
| Mar 2015 | - | -$5.04 M(-7.3%) | -$26.33 M(-12.9%) |
| Dec 2014 | -$30.25 M(-30.0%) | -$5.44 M(+10.3%) | -$30.25 M(-10.9%) |
| Sept 2014 | - | -$4.93 M(-54.8%) | -$33.93 M(-10.4%) |
| June 2014 | - | -$10.91 M(+21.9%) | -$37.89 M(-4.5%) |
| Mar 2014 | - | -$8.96 M(-1.9%) | -$39.68 M(-8.2%) |
| Dec 2013 | -$43.22 M | -$9.13 M(+2.7%) | -$43.22 M(-7.7%) |
| Sept 2013 | - | -$8.89 M(-30.1%) | -$46.84 M(-7.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | - | -$12.71 M(+1.8%) | -$50.53 M(+2.6%) |
| Mar 2013 | - | -$12.49 M(-2.1%) | -$49.26 M(+0.6%) |
| Dec 2012 | -$48.98 M(+40.5%) | -$12.76 M(+1.4%) | -$48.98 M(+2.0%) |
| Sept 2012 | - | -$12.58 M(+10.0%) | -$48.01 M(+4.2%) |
| June 2012 | - | -$11.43 M(-6.4%) | -$46.09 M(+2.3%) |
| Mar 2012 | - | -$12.21 M(+3.6%) | -$45.06 M(+27.2%) |
| Dec 2011 | -$34.86 M(-309.1%) | -$11.78 M(+10.6%) | -$35.43 M(+14.7%) |
| Sept 2011 | - | -$10.66 M(+2.3%) | -$30.89 M(+8.6%) |
| June 2011 | - | -$10.41 M(+303.7%) | -$28.44 M(-7.1%) |
| Mar 2011 | - | -$2.58 M(-64.4%) | -$30.61 M(-283.6%) |
| Dec 2010 | $16.67 M(-137.1%) | -$7.24 M(-11.8%) | $16.67 M(+24.2%) |
| Sept 2010 | - | -$8.21 M(-34.8%) | $13.42 M(+46.0%) |
| June 2010 | - | -$12.59 M(-128.2%) | $9.19 M(-15.6%) |
| Mar 2010 | - | $44.70 M(-526.3%) | $10.89 M(-124.3%) |
| Dec 2009 | -$44.90 M(-15.2%) | -$10.49 M(-15.7%) | -$44.90 M(+12.5%) |
| Sept 2009 | - | -$12.44 M(+14.2%) | -$39.90 M(-0.1%) |
| June 2009 | - | -$10.89 M(-1.7%) | -$39.95 M(-7.1%) |
| Mar 2009 | - | -$11.08 M(+102.0%) | -$43.00 M(-6.2%) |
| Dec 2008 | -$52.92 M(+19.3%) | -$5.49 M(-56.1%) | -$45.83 M(-7.5%) |
| Sept 2008 | - | -$12.49 M(-10.4%) | -$49.54 M(+2.1%) |
| June 2008 | - | -$13.94 M(+0.2%) | -$48.53 M(+7.5%) |
| Mar 2008 | - | -$13.91 M(+51.3%) | -$45.15 M(+10.6%) |
| Dec 2007 | -$44.35 M(+15.2%) | -$9.20 M(-19.9%) | -$40.82 M(+9.5%) |
| Sept 2007 | - | -$11.48 M(+8.6%) | -$37.28 M(-0.1%) |
| June 2007 | - | -$10.57 M(+10.3%) | -$37.33 M(-0.3%) |
| Mar 2007 | - | -$9.58 M(+69.3%) | -$37.45 M(-2.8%) |
| Dec 2006 | -$38.52 M(-0.1%) | -$5.66 M(-50.9%) | -$38.52 M(-6.9%) |
| Sept 2006 | - | -$11.53 M(+7.9%) | -$41.35 M(+3.1%) |
| June 2006 | - | -$10.68 M(+0.3%) | -$40.11 M(+0.8%) |
| Mar 2006 | - | -$10.65 M(+25.4%) | -$39.80 M(+3.2%) |
| Dec 2005 | -$38.56 M(+65.5%) | -$8.49 M(-17.4%) | -$38.56 M(+3.5%) |
| Sept 2005 | - | -$10.29 M(-0.8%) | -$37.26 M(+15.1%) |
| June 2005 | - | -$10.37 M(+10.3%) | -$32.37 M(+21.8%) |
| Mar 2005 | - | -$9.40 M(+30.7%) | -$26.57 M(+15.0%) |
| Dec 2004 | -$23.29 M(+66.6%) | -$7.20 M(+33.4%) | -$23.11 M(+13.1%) |
| Sept 2004 | - | -$5.39 M(+17.8%) | -$20.43 M(+11.1%) |
| June 2004 | - | -$4.58 M(-22.9%) | -$18.38 M(+6.9%) |
| Mar 2004 | - | -$5.94 M(+31.4%) | -$17.19 M(+23.0%) |
| Dec 2003 | -$13.98 M(+19.6%) | -$4.52 M(+34.9%) | -$13.98 M(+47.7%) |
| Sept 2003 | - | -$3.35 M(-1.3%) | -$9.46 M(+54.8%) |
| June 2003 | - | -$3.39 M(+24.5%) | -$6.11 M(+124.5%) |
| Mar 2003 | - | -$2.72 M | -$2.72 M |
| Dec 2002 | -$11.69 M(+43.5%) | - | - |
| Dec 2001 | -$8.15 M(+109.8%) | - | - |
| Dec 2000 | -$3.88 M(+401.6%) | - | - |
| Dec 1999 | -$774.00 K | - | - |
FAQ
- What is Oncternal Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Oncternal Therapeutics?
- What is Oncternal Therapeutics annual EBITDA year-on-year change?
- What is Oncternal Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Oncternal Therapeutics?
- What is Oncternal Therapeutics quarterly EBITDA year-on-year change?
- What is Oncternal Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Oncternal Therapeutics?
- What is Oncternal Therapeutics TTM EBITDA year-on-year change?
What is Oncternal Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ONCT is -$41.71 M
What is the all time high annual EBITDA for Oncternal Therapeutics?
Oncternal Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $16.67 M
What is Oncternal Therapeutics annual EBITDA year-on-year change?
Over the past year, ONCT annual earnings before interest, taxes, depreciation & amortization has changed by +$3.23 M (+7.19%)
What is Oncternal Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ONCT is -$8.68 M
What is the all time high quarterly EBITDA for Oncternal Therapeutics?
Oncternal Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $44.70 M
What is Oncternal Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ONCT quarterly earnings before interest, taxes, depreciation & amortization has changed by +$1.71 M (+16.45%)
What is Oncternal Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ONCT is -$35.96 M
What is the all time high TTM EBITDA for Oncternal Therapeutics?
Oncternal Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $16.67 M
What is Oncternal Therapeutics TTM EBITDA year-on-year change?
Over the past year, ONCT TTM earnings before interest, taxes, depreciation & amortization has changed by +$8.03 M (+18.26%)